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www.elsevier.com/locate/critrevoncAbstract
Increase of the Prostatic Specific Antigen (PSA) is a non-invasive, sensitive and specific markers for prostatic diseases, including
prostatic cancer. However, age-related Benign Prostatic Hyperplasia (BPH), as well as prostatitis, may at the same time alter PSA
values. The aim of this study was to evaluate the relationship between ageing and PSA, and whether age-specific upper normal limits
of PSA should be considered for elderly patients. We evaluated 569 consecutive subjects aged 60 years or more (mean age 74.2 years)
who were free from malignant prostatic disease, without clinical evidence of prostatic phlogosis and who were not receiving PSA
levels affecting drugs. All patients underwent Digital Rectal Examination (DRE) and Trans-Rectal Ultrasonography (TRU), with
determination of the three prostatic diameters, the Maximum Adenoma Diameter (MAD) and calculation of the prostatic volume
(PV) by the ellipsoid formula. PSA was determined in all patients before DRE and TRU, and the PSA free ratio was determined in
those with total PSA values /4 ng/ml. The PSA density was calculated according to the formula PSA/PV. One hundred and
seventy-nine subjects (31.6%) were found to have PSA values /4 ng/ml: among them, 26 (14.5%) had values exceeding 10 ng/ml.
Age was slightly correlated with PV (PB/0.05), but not with PSA values. On the contrary, PSA values were strongly related with PV
and MAD (PB/0.01 both). Mean PSA-free ratio was 16.39/6.0% and most of patients had values in the so-called ‘grey zone’ of
discrimination between benignity and malignity.* Corresponding author. Present address: Department of Medical and Surgical Disciplines, Geriatric Section, University of Torino, Corso
Dogliotti 14, Turin 100126, Italy. Tel.: /11-663-7140/11-633-6734; fax: /11-696-1045.
E-mail address: fabrizio.fabris@unito.it (F. Fabris).
1 Present address: Institute of Gerontology, University of Turin, Corso Bramante 88, 10126, Torino, Italy. Tel.:/33-011-6337140; fax:/33-011-
6961045.
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M. Bo et al. / Critical Reviews in Oncology/Hematology 47 (2003) 207/211208Elevated PSA levels are common in older subjects without evidence of prostatic malignancy; PSA values are poorly affected by
age itself and strongly correlated with increasing PV. These results suggest the possibility to consider as indicative of benignity PSA
values between 4 and 10 ng/ml, when these values are associated with relevant increase of PV and with PSA-free ratio greater than
10%.
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Most of prostatic diseases occur in advanced age. The
Prostatic Specific Antigen (PSA), sinthetyzed only by
prostatic gland cells, is currently regarded as a sensitive
and specific markers for prostatic diseases, including
Benign Prostatic Hypertrophia (BPH), prostatitis and
cancer. Although very sensitive, it is not at all specific
for a special prostatic disease. Currently total PSA
values /4 ng/ml are considered pathologic, and when
exceeding 10 ng/ml are strongly suggestive of malig-
nancy. However, ageing is associated with physiological
hypertrophic modifications of the prostate and BPH is
extremely common among older subjects [1,2]. It is
widely demonstrated that BPH may be associated with
slight increases in PSA values [3,4]. Oesterling [5] found
a positive correlation between PSA and prostatic
volume (PV), whereas Dalkin et al. [6] and Crawford
[7] proposed age-specific PSA ranges.
There remain important areas of uncertainty about
the relationship between ageing, BPH and ‘normal’ PSA
values. The aim of this study was to evaluate primarily
the relationship between ageing, increasing PV and PSA
values, and, secondary, whether these relationships
might justify the adoption of age-specific PSA values.
2. Subjects and methods
In the period between March 1999 and May 2000, 569
consecutive patients were enrolled among those ad-
mitted to the Geriatric Acute Ward and to the Urology
Department of Molinette, a university-teaching hospital
in Turin, according to the following inclusion criteria:
age /60 and 5/90 years, Digital Rectal Examination
(DRE) negative for suspected malignancy, absence of
prostatic malignancy on the basis of postoperative
histological specimens and/or negative bioptic response
in patients with PSA values exceeding 4 ng/ml, absence
of clinical and histological evidences of prostatic phlo-
gosis [8] and absence of current or previous medical
treatment with drugs which could affect PSA values (5-a
reductase inhibitors, GnRH agonists, antiandrogens,
progestative agents and a-channel blockers) [9,10].
In all patients serum total PSA was determined using
immunoenzymatic assay (Immulite 2000); in patients
whose total PSA values were greater than 4 ng/ml, the
PSA free ratio was also determined. Blood sample for
PSA determination were obtained before DRE and
Trans-Rectal Ultrasonography (TRU) to avoid false
positive results due to the compression of the gland.
DRE was performed in all patients by qualified urolo-
gist, aimed to exclude objective evidence suggestive of
malignancy or phlogosis, and to evaluate volume and
consistence of the prostate. TRU was performed by
radiologist qualified in this investigation using a 5 MHz
probe and the following measures were determined:
anteroposterior (A ), transversal (B ) and longitudinal
(C ) diameters of the whole prostate and the Maximum
Adenoma Diameter (MAD). The PV was calculated
according to the ellipsoid formula [11]: PV/4/3p/A /
2/B /2/C /2. The TRU examination was completed by
obtaining multiple bioptic specimens to rule out the
presence of malignancy in those patients who were
suspected for cancer in reason of high PSA values and/
or abnormal DRE.
The PSA density (PSAD) was calculated by dividing
the total PSA value for the volume of the prostate
(PSAD/PSA/PV).
Statistical analysis was performed by Student t-test,
ANOVA and evaluation of the Pearson’s index of linear
correlation ‘r ’, for continuous variables, using SPSS/
PC/ packaging.
3. Results
Five hundred and sixty-nine subjects (mean age
74.29/6.8 years, range 60/90 years) participated at the
study. The following mean values (9/ standard devia-
tion) were observed: PSA 3.719/3.07 ng/ml; PV 55.59/
29.9 ml (upper normal limit: 15 ml [12]; MAD 3.69/1.2
cm; and PSAD 0.0679/0.055 ng/ml.
Three hundred and ninety subjects (68.4%) had total
PSA values within the upper normal limit (5/4 ng/ml),
while 179 patients (31.6%) had PSA values exceeding
this limit. Among these latter subjects, 153 (85.5%) had
PSA values /4 and 5/10 ng/ml and 26 (14.5%) had
total PSA values /10 ng/ml.
Only 16 subjects (2.8%) had PV within the upper
normal limit (15 ml); moderate and severe increases of
the PV were observed, respectively in 449 (80%) and in
104 (17.2%) patients.
Age was found to be weakly but significantly corre-
lated with increasing PV (PB/0.05), but not with total
PSA values, whereas PSA values were strongly corre-
lated either with PV and with MAD (PB/0.01 both)
(Fig. 1). Table 1 shows mean PV and MAD values
according to PSA ranges commonly used in clinical
settings (5/4, /4 and 5/10, /10 ng/ml): either PV and
MAD values increased significantly (PB/0.0001 both)
according to the increasing values of PSA considered.
The mean PSA free ratio in the 179 subjects with total
PSA /4 ng/ml was 16.39/6.0%; most of these subjects
had PSA free ratio values between the 25th and the 75th
percentile, (respectively 12.3 and 20.2%). No significant
correlations were observed between PSA free values and
other variables investigated (PV, age, PSA and MAD)
with the exception of a slight inverse correlation with
PSAD.
4. Discussion
In this study we observed that roughly a third of
subjects over 60 years had PSA values exceeding the
upper normal limit. Despite the high prevalence of this
alteration, results of the present study indicate that this
finding should not be considered ageing-related but
rather age-associated disease related. In fact, accord-
ingly with previous studies [3,4,13], we found strong
Fig. 1. Pearson’s correlation between the variables (PSA, age, PV, maximum diameter of adenoma).
Table 1
Values (media9/standard deviation) of PV and maximum diameter of adenoma in relation with PSA expressed for groups
PSA5/4 ng/ml (n/390) 4/ PSA5/10 ng/ml (n/153) PSA /10 ng/ml (n/26) F P
Volume (ml) 45.949/23.35 72.109/30.44 101.729/4.81 53.38 B/0.0001
Diameter of adenoma (cm) 3.299/1.08 4.199/0.97 4.819/1.50 28.03 B/0.0001
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correlations of PSA values with PV and MAD values,
but not with age itself [14,15]. Moreover, the absence of
a correlation between age and PSAD (which is a
volume-corrected PSA) strongly reinforces this conclu-
sion. Therefore, as suggested in previous papers
[3,4,13,16], it is likely the increased amount of secreting
tissue, as it occurs in BPH, is the main responsible for
these slight to moderate increases in PSA values.
Although the increase of PSA values may be considered
slight to moderate (5/10 ng/ml) in most of patients, a
small group of subjects (4.5%) may have more severe
increases (/10 ng/ml). The PSA free ratio is of limited
utility in these patients: in fact in most subjects with
PSA values exceeding the upper normal limit; the PSA
free ratio values were within the so-called grey zone.
These data indicate that in older subjects values of PSA
exceeding the upper normal limit are commonly ob-
served in absence of malignant disease, thereby increas-
ing the likelihood of false positive results. In our view,
these results provide further arguments against ‘abuse’
of PSA as diagnostic or screening tool in elderly
subjects. Whether routine screening of all men is cost-
effective remains controversial, especially for men age 75
and older [17]. If early detection of prostatic cancer
improves health outcomes, the population most likely to
benefit from screening will be men 50/70 years of age
who were at higher risk. Older men and men with other
significant medical problems who have limited life-
expectancy are unlikely to benefit from screening [18].
Some limitations of this study should be discussed.
The cross sectional design of this study and the absence
of prospective observation do not allow to verify the
true absence of malignancy. In fact, even the negativity
of multiple bioptic specimens does not rule out,
particularly in severe BPH, the possibility of a carci-
noma in situ. The adoption of a hospital-derived sample
might have facilitated the selection of subjects with more
severe diseases. Finally, the absence of a comparison
with a group of consecutive patients with prostate
cancer does not seem to limit the validity of the results
observed.
With these limits, this study showed that slight to
moderate increases of PSA values are common in older
subjects without evidence of malignancy and that they
are mainly accounted for by a greater PV. On these
basis, the adoption of age-specific range for PSA values
is not recommended. This possibility of false positive
results further reduces the indications to use PSA as a
diagnostic screening tool in elderly subjects.
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